Matching slides 303,780
Current window 207,661-207,690
Pages 10,126
Rows per page 30
Component: Titleclear collectionreset all

Component

207,661-207,690 of 303,780

filter-aware
14
Citi | Investment Banking Pitch Book | 20 slidesCiti | Investment Banking Pitch Book | 20 slides · Citi
Consulting deck Investment bank Beat · Solution & ApproachLoop · Mece Breakdown1 hit
15
The slide uses a table-like structure with categories on the left and bulleted assumptions on the right.Citi | Investment Banking Pitch Book | 20 slides · Citi
Consulting deck Investment bank Beat · Solution & ApproachLoop · Mece Breakdown1 hit
16
Includes detailed footnotes regarding adjustments, tax rates, and source data.Citi | Investment Banking Pitch Book | 20 slides · Citi
Consulting deck Investment bank Beat · Solution & ApproachLoop · Mece Breakdown1 hit
17
Includes a disclaimer about the preliminary nature of the data and specific assumptions regarding tax rates and debt.Citi | Investment Banking Pitch Book | 20 slides · Citi
Consulting deck Investment bank Beat · Solution & Approach1 hit
18
Citi | Investment Banking Pitch Book | 20 slidesCiti | Investment Banking Pitch Book | 20 slides · Citi
Consulting deck Investment bank Beat · Evidence & Proof1 hit
19
Includes disclaimer about preliminary nature and data sources.Citi | Investment Banking Pitch Book | 20 slides · Citi
Consulting deck Investment bank Beat · Evidence & Proof1 hit
20
Includes a pie chart showing ownership distribution and a table detailing the top 25 investors by name, type, and percentage.Citi | Investment Banking Pitch Book | 20 slides · Citi
Consulting deck Investment bank 1 hit
01
Slide 1
Comera | Investor Presentation Deck | 22 slidesComera | Investor Presentation Deck | 22 slides · Comera Life Sciences
Pitch deck Investor relations Beat · Attention1 hit
02
Comera | Investor Presentation Deck | 22 slidesComera | Investor Presentation Deck | 22 slides · Comera Life Sciences
Pitch deck Investor relations 1 hit
03
Comera | Investor Presentation Deck | 22 slidesComera | Investor Presentation Deck | 22 slides · Comera Life Sciences
Pitch deck Investor relations Beat · Interest1 hit
01
Slide 1
Includes a molecular visualization graphic.Compass Therapeutics | Investor Presentation Deck | 20 slides · Compass Therapeutics
Pitch deck Investor relations 1 hit
02
Compass Therapeutics | Investor Presentation Deck | 20 slidesCompass Therapeutics | Investor Presentation Deck | 20 slides · Compass Therapeutics
Pitch deck Investor relations 1 hit
03
The slide explains the mechanism of action for a bispecific antibody, contrasting single-target blockade with dual-target blockade.Compass Therapeutics | Investor Presentation Deck | 20 slides · Compass Therapeutics
Pitch deck Investor relations Beat · Solution1 hit
04
The slide outlines a standard Simon 2-stage design, a common statistical framework in oncology trials to allow for early stopping for futility.Compass Therapeutics | Investor Presentation Deck | 20 slides · Compass Therapeutics
Pitch deck Investor relations Beat · Product1 hit
05
The table is split into two columns, both representing the same cohort of 24 patients.Compass Therapeutics | Investor Presentation Deck | 20 slides · Compass Therapeutics
Pitch deck Investor relations Beat · Product1 hit
06
The chart is a classic waterfall plot used in oncology clinical trials to demonstrate efficacy.Compass Therapeutics | Investor Presentation Deck | 20 slides · Compass Therapeutics
Pitch deck Investor relations Beat · ProductLoop · Cost Of Inaction1 hit
07
Clinical trial data visualization showing patient-level progression, response (PR, SD, PD), and status (death, ongoing).Compass Therapeutics | Investor Presentation Deck | 20 slides · Compass Therapeutics
Pitch deck Investor relations Beat · ProductLoop · Cost Of Inaction1 hit
08
Clinical trial data presentation.Compass Therapeutics | Investor Presentation Deck | 20 slides · Compass Therapeutics
Pitch deck Investor relations Beat · ProductLoop · Cost Of Inaction1 hit
09
Standard clinical trial survival analysis plots.Compass Therapeutics | Investor Presentation Deck | 20 slides · Compass Therapeutics
Pitch deck Investor relations 1 hit
10
The slide compares clinical trial data for a specific combination therapy against known label safety profiles of individual components.Compass Therapeutics | Investor Presentation Deck | 20 slides · Compass Therapeutics
Pitch deck Investor relations 1 hit
11
Comparison of CTX-009 efficacy metrics (ORR, PFS, OS) against FOLFOX and TOPAZ-1 benchmarks.Compass Therapeutics | Investor Presentation Deck | 20 slides · Compass Therapeutics
Pitch deck Investor relations 1 hit
12
The diagram outlines the randomization, treatment regimen, disease progression assessment, and study endpoints.Compass Therapeutics | Investor Presentation Deck | 20 slides · Compass Therapeutics
Pitch deck Investor relations 1 hit
13
The slide uses a table for market sizing and a structured layout to contrast 1L and 2L treatment pathways.Compass Therapeutics | Investor Presentation Deck | 20 slides · Compass Therapeutics
Pitch deck Investor relations Beat · Problem1 hit
14
The table highlights Partial Response (PR) rates with a red border, emphasizing clinical activity.Compass Therapeutics | Investor Presentation Deck | 20 slides · Compass Therapeutics
Pitch deck Investor relations Beat · Market Size1 hit
15
The slide depicts a standard Simon 2-stage design, a common statistical framework for phase II oncology trials.Compass Therapeutics | Investor Presentation Deck | 20 slides · Compass Therapeutics
Pitch deck Investor relations Beat · Market Size1 hit
16
The slide provides epidemiological data and clinical treatment pathways for CRC, highlighting the limited efficacy of current 3L treatments.Compass Therapeutics | Investor Presentation Deck | 20 slides · Compass Therapeutics
Pitch deck Investor relations Beat · Market Size1 hit
17
The slide uses a three-column layout to represent distinct clinical study tracks with initiation dates.Compass Therapeutics | Investor Presentation Deck | 20 slides · Compass Therapeutics
Pitch deck Investor relations Loop · Quick Win Big Bet1 hit
18
This appears to be a slide introducing an advisor or team member.Compass Therapeutics | Investor Presentation Deck | 20 slides · Compass Therapeutics
Pitch deck Investor relations Beat · Team1 hit
19
The table compares a small N=24 study (CTX-009) against larger historical studies (N=81 to N=341).Compass Therapeutics | Investor Presentation Deck | 20 slides · Compass Therapeutics
Pitch deck Investor relations Beat · Competition1 hit
20
Compass Therapeutics | Investor Presentation Deck | 20 slidesCompass Therapeutics | Investor Presentation Deck | 20 slides · Compass Therapeutics
Pitch deck Investor relations 1 hit